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Hepatitis B virus (HBV)-related acute liver failure (HBV-ALF) may occur after acute HBV
infection (AHBV-ALF) or during an exacerbation of chronic HBV infection (CHBV-ALF).
Clinical differentiation of the two is often difﬁcult if a previous history of HBV is not
available. Quantitative measurements of immunoglobulin M (IgM) anti–hepatitis B core
antibody (anti-HBc) titers and of HBV viral loads (VLs) might allow the separation of
AHBV-ALF from CHBV-ALF. Of 1,602 patients with ALF, 60 met clinical criteria for
AHBV-ALF and 27 for CHBV-ALF. Sera were available on 47 and 23 patients, respectively.
A quantitative immunoassay was used to determine IgM anti-HBc levels, and real-time po-
lymerase chain reaction (rtPCR) was used to determine HBV VLs. AHBV-ALFs had much
higher IgM anti-HBc titers than CHBV-ALFs (signal-to-noise [S/N] ratio median: 88.5;
range, 0-1,120 versus 1.3, 0-750; P < 0.001); a cut point for a S/N ratio of 5.0 correctly
identiﬁed 44 of 46 (96%) AHBV-ALFs and 16 of 23 (70%) CHBV-ALFs; the area under
the receiver operator characteristic curve was 0.86 (P < 0.001). AHBV-ALF median admis-
sion VL was 3.9 (0-8.1) log10 IU/mL versus 5.2 (2.0-8.7) log10 IU/mL for CHBV-ALF
(P < 0.025). Twenty percent (12 of 60) of the AHBV-ALF group had no hepatitis B surface
antigen (HBsAg) detectable on admission to study, wheras no CHBV-ALF patients
experienced HBsAg clearance. Rates of transplant-free survival were 33% (20 of 60) for
AHBV-ALF versus 11% (3 of 27) for CHBV-ALF (P 5 0.030). Conclusions: AHBV-ALF
and CHBV-ALF differ markedly in IgM anti-HBc titers, in HBV VLs, and in prognosis,
suggesting that the two forms are, indeed, different entities that might each have a unique
pathogenesis. (HEPATOLOGY 2012;55:676-684)
H
epatitis B virus (HBV)-related acute liver fail-
ure (ALF) constitutes 1% of those experienc-
ing acute or chronic HBV (AHBV-ALF and
CHBV-ALF, respectively).1,2 Patients who have AHBV-
ALF, as well as those with an acute exacerbation (i.e.,
disease ﬂare) of CHBV-ALF, cannot be distinguished on
clinical grounds without historical or histological evi-
dence for chronicity, which may be lacking in acutely ill
patients. CHBV-ALF may occur spontaneously or as a
result of the effect of immunosuppression on viral repli-
cation and immunity.1,2 We postulated that serological
or virological factors might better separate acute
Abbreviations:: AHBV-ALF, acute HBV infection; ALF, acute liver failure; ALT, alanine aminotransferase; ANCOVA, analysis of covariance; anti-HBc, anti–
hepatitis B core antibody; AST, aspartate aminotransferase; AUROC, area under the receiver operating characteristic curve; CHBV-ALF, chronic HBV infection;
HCC, hepatocellular carcinoma; CI, conﬁdence interval; ELISA, enzyme-linked immunosorbent assay; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface
antigen; HBV, hepatitis B virus; IgM, immunoglobulin M; HIV, human immunodeﬁciency virus; INR, international normalized ratio; LLD, lower limit of
detection; OR, odds ratio; ROC, receiver operating characteristic; rtPCR, real-time polymerase chain reaction; S/N, signal-to-noise ratio; VL, viral load.
From the 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; 2Department of Clinical Sciences and Psychiatry,
University of Texas Southwestern Medical Center, Dallas, TX; 3Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI; and
4Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX.
Received January 19, 2011; accepted September 27, 2011.
This study was funded by a National Institutes of Health grant (DK U-01 58369) for the Acute Liver Failure Study Group provided by the National Institute
of Diabetes and Digestive and Kidney Diseases. Additional funding was provided by the Tips Fund of the Northwestern Medical Foundation, the Jeanne Roberts
and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation, and T-32 DK007745-12 (to D.D.).
*Members of the Acute Liver Failure Study Group are listed in the Appendix.
676
infections from acute exacerbations of chronic disease
when they present as ALF, because the immune patho-
genesis of each may be somewhat different.
During the natural history of HBV infection, immune
response and degree of liver injury, as exempliﬁed by ami-
notransferase levels, are considered to be roughly inversely
proportional to HBV viral loads (VLs), which vary widely
from over 1 billion copies in immune-tolerant patients to
barely detectable or negative in inactive carriers.3-5 A strong
adaptive immune response results in rapid clearance of
hepatitis B surface antigen (HBsAg) and early detection of
antibodies to HBsAg in some patients with HBV-ALF.6 In
support of this, low or undetectable HBV VLs or HBsAg
can be observed in approximately 20% of such patients.1,7
By contrast, in CHBV-ALF, accompanied by immunosup-
pression, the virus may become directly cytopathic, whereas
liver injury in chronic infected patients who are not immu-
nosuppressed is still presumed to be immune mediated.8
Detection of immunoglobulin M (IgM) anti–hepati-
tis B core antibody (anti-HBc), measured by enzyme-
linked immunosorbent assay (ELISA), is critical in dif-
ferentiating AHBV-ALF from CHBV-ALF. However,
patients with CHBV-ALF sometimes demonstrate IgM
anti-HBc positivity.9,10 Previous semiquantitative assays
described the longitudinal changes in IgM anti-HBc,
but no studies have provided direct assessments of
IgM anti-HBc quantitation in patients with ALF.11
Use of a semiquantitative IgM anti-HBc ELISA, rather
than a single cut-off value, might better distinguish
AHBV-ALF from CHBV-ALF. In addition, measure-
ment of VLs across a wide dynamic range has not
been studied extensively and might provide a second
tool to separate AHBV-ALF from CHBV-ALF.
In the present study, we classiﬁed a large group of
patients, all of whom met criteria for HBV-related
ALF, separating them on historical and clinical
grounds into either AHBV-ALF or CHBV-ALF. We
then determined whether quantitative measurement of
IgM anti-HBc or HBV VLs (or a ratio combining the
two), performed in blinded fashion, could help to dis-
tinguish between AHBV-ALF and CHBV-ALF.
Patients and Methods
Patients. Between January 1998 and December
2009, 23 sites in the U.S. ALF Study Group enrolled
1,602 patients with ALF comprising all etiologies, to
study, in a prospective fashion, their clinical characteris-
tics and outcomes. The deﬁnition of ALF included
severe acute liver injury without known cirrhosis, with a
duration of illness of <26 weeks accompanied by he-
patic encephalopathy and coagulopathy (prothrombin
time 15 seconds or international normalized ratio
[INR] 1.5)12; 105 patients were screened and 87
patients with HBV-ALF met criteria for enrollment, as
outlined in Fig. 1. All patients were either IgM anti-
HBc positive or HBsAg positive or both; 12 HBsAg-
negative/IgM anti-HBc–positive patients were consid-
ered to represent early viral clearance.7 The clinical dis-
tinction between AHBV-ALF and CHBV-ALF was
made after careful review of each case report form by
one of us (W.M.L.), using speciﬁc criteria from the clin-
ical history. Chronic patients either had a known history
of having chronic disease (i.e., previous evidence of
HBV at least 6 months before admission to study) or,
in the setting of immunosuppression or human immu-
nodeﬁciency virus (HIV) infection, ALF was assumed
to represent chronic infection. The AHBV-ALF group
was characterized by age <50 plus high-risk behaviors,
such as injection drug use, multiple sex partners, or sex
with a known HBV carrier; in the absence of chronic
disease or high-risk behavior, older age (>50 years) and
Asian ethnicity were deemed to indicate chronicity. Fif-
teen patients could not be characterized using these cri-
teria. The reviewer was unaware of VLs or quantitative
IgM anti-HBc levels when the adjudication was made.
Standard molecular analyses, using polymerase chain
reaction (PCR) followed by standard consensus sequenc-
ing, were used for viral genotyping (n ¼ 71) and deter-
mining the presence of hepatitis Be antigen (HBeAg)-
negative mutations (n ¼ 68).
Because patients, by deﬁnition, were encephalo-
pathic, informed consent was obtained from next of
kin before study enrollment. The study was approved
by the local institutional review board at each site.
Detailed demographics as well as clinical and outcome
data of all HBV-related ALF patients were available
from the coordinating center (University of Texas
Southwestern Medical Center, Dallas, TX). Serum
samples were collected serially for up to 7 days after
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admission to study and were stored at 80C before
retrieval from the coordinating site for the study.
Admission sera used for VL and IgM anti-HBc deter-
minations were considered to be the ﬁrst available se-
rum samples after enrollment in the study (Fig. 1).
Spontaneous survival indicated survival without trans-
plantation, whereas overall survival included all those
surviving at 3 weeks after admission to study, regard-
less of transplantation.
Laboratory Testing.
Measurement of IgM anti-HBc titers.. IgM anti-HBc
titers were measured using the ADVIA Centaur IgM
anti-HBc assay (Siemens Diagnostics, Tarrytown, NY).
Brieﬂy, this assay is an indirect IgM capture immuno-
assay using a two-step format, including biotinylated
antihuman IgM and a solid phase containing streptavi-
din-coated microparticles. An index value of 1 is
considered to be reactive, 0.8-0.99 is a ‘‘gray zone’’
that requires retesting, and <0.8 is nonreactive. Each
serum sample of 200 lL was run according to assay
instructions to determine the index value (i.e., signal-
to-noise [S/N] ratio). Sample results beyond the
dynamic range of 9.0 (index value range: 0.05-9.0)
were serially diluted with a 1:10 dilution using pooled
serum that had been tested for HBc IgM antibody and
found negative. The ﬁnal index value was multiplied
by the appropriate dilution factor to give a ﬁnal ‘‘cal-
culated’’ index result.
Quantiﬁcation of HBV VL by real-time PCR.. Sera
collected in serial fashion on days 1 through 4 after
admission to study were quantiﬁed using an estab-
lished real-time PCR (rtPCR) protocol.13 Each serum
sample was run in triplicate, and the median value was
selected. Viral DNA extracted from serum was ampli-
ﬁed and quantiﬁed in a 7900HT Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA). The
dynamic range of the assay was 25 to 2  107 IU/mL.
Statistical Analyses. Statistical analyses were per-
formed using IBM SPSS Statistics 19.0 (SPSS, Inc.,
Chicago, IL), SAS 9.2 (SAS Institute, Inc., Cary, NC),
and StatXact V8 (Cytel Inc., Cambridge, MA). The
Mann-Whitney U test was used to compare groups
(AHBV-ALF versus all CHBV-ALF or only the non-
immunosuppressed CHBV-ALF group) on continuous
measures, including HBV VL and IgM anti-HBc lev-
els. Chi-squared or Fisher’s exact tests (when appropri-
ate) were employed to compare groups on categorical
measures. The receiver operator characteristic (ROC)
curve and the test for the area under the receiver oper-
ator characteristic curve (AUROC) were used to
describe the relationship between the true-positive rate
and the false-positive rate in the prediction of group
membership (AHBV-ALF versus overall CHBV-ALF),
using the continuous-measures IgM anti-HBc levels
and the ratio of IgM anti-HBc to VL; standard errors
for areas were estimated using a nonparametric
method and testing the null hypothesis of the true
area equal to 0.50. A mixed-model analysis of covari-
ance (ANCOVA) was used to determine the effects of
time (i.e., baseline, day 2, and day 4) on log10 VLs
for AHBV-ALF versus CHBV-ALF, with subject at
each time point treated as a random effect. Covariates
considered in this model were patient age, admission
IgM anti-HBc levels, and use of nucleoside (tide) ana-
log; covariates remained in the model if P < 0.15.
Logistic regression analysis was employed to predict
AHBV-ALF versus CHBV-ALF using admission log10
VLs, admission IgM anti-HBc titers, admission HBsAg
status, patient age, and HBV genotypes (i.e., A, B, and
C) as covariates; Hosmer-Lemeshow P values were
provided to demonstrate the ﬁt of the model to the
Fig. 1. Study schema. Of the 1,602 ALF patients in the U.S. ALF
Study Group, there were 105 HBV-ALF patients identiﬁed. Eighteen
were excluded: 2 coinfected with hepatitis C virus, 1 determined to
have HCC, and 15 who we were unable to deﬁne as either acute or
chronic. Sixty were identiﬁed as AHBV-ALF, of whom 47 had sera col-
lected on admission and 14 had sera collected serially up to day 49.
Twenty-seven patients were identiﬁed as CHBV-ALF; 9 appeared to
show spontaneous exacerbation (nonimmunosuppressed CHBV-ALF),
and 18 were considered immunosuppressed; admission and serial
sera over 4 days in these groups are also listed.
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data. AUROC analysis was used to examine the pre-
dictions made by the logistic regression analysis in dis-
tinguishing between the AHBV-ALF and CHBV-ALF
groups. For all statistical tests, a P value <0.05 was
considered statistically signiﬁcant, unless otherwise
stated. VL is expressed as the median (range) (log10
IU/mL), unless otherwise stated.
Results
Analysis of the Two Groups: AHBV-ALF and
CHBV-ALF. Initially, data on 105 patients were avail-
able: We excluded 2 HBVþHCV coinfected patients, 1
patient whose liver biopsy later revealed extensive hepa-
tocellular carcinoma (HCC) and 15 who could not be
characterized as to their acute or chronic status (Fig. 1).
Comparing these 15 unclassiﬁed cases to the remaining
87, race (P ¼ 0.223) and gender (P ¼ 0.576) were not
different; however, the median age (range) for the 15
not included was signiﬁcantly older than those that
remained in the analysis (55.5 [40-69] versus 41 [17-
71], respectively; P ¼ 0.001). Thus, 60 met criteria for
the AHBV-ALF group and 27 for the CHBV-ALF
group. No patient in either group was coinfected with
hepatitis A, D, or E viruses using standard tests. Liver
histology, available for 31 of the overall group, did not
show evidence of cirrhosis in any patient.
The 27 patients within the overall CHBV-ALF
group included 14 who were known to have CHBV-
ALF. Nine experienced spontaneous acute exacerbation
(unexplained and without immunosuppression),
whereas the remaining 18 experienced immunosup-
pression-related ALF: 13 had received either chemo-
therapy for leukemia or lymphoma (n ¼ 9), or corti-
costeroids for Crohn’s disease, asthma, Guillain-Barre
syndrome, and unknown (1 each); 5 had concomitant
HIV infection. Of interest, 6 of the 18 immunosu-
pressed patients were unaware of their diagnosis of
CHBV-ALF at the time of presentation. The remain-
ing 9 CHBV-ALF patients with apparent acute or
chronic disease included 5 known to have CHBV-ALF.
Among the 60 that were categorized as having true
CHBV-ALF, 23 had a history of injection drug use
(only) and 19 had a history of high-risk sexual behav-
ior or sex with a known HBV individual; in 5, both
risk factors were positive.
In general, clinical and laboratory features, such as
length of illness and INR levels, aspartate aminotrans-
ferase (AST) levels, bilirubin, and creatinine, did not
differ between the 60 patients considered to have
AHBV-ALF and the 27 in the overall CHBV-ALF
group (Table 1). However, alanine aminotransferase
(ALT) levels and albumin levels were higher in the
AHBV-ALF patients than the CHBV-ALF patients.
There were few apparent differences in virologic or
host features found between the two chronic sub-
groups (9 nonimmunosuppressed versus 18 patients
with immunosuppression), although viral loads at
admission were lower in the nonimmunosuppressed
group. For the remaining statistical analyses, we com-
bined the CHBV-ALF subgroups, except where noted.
Demographics and HBV Genotypes. Certain
important demographic and virologic characteristics dif-
fered between the two main groups: AHBV-ALF
patients were younger (median, 36 years; range, 17-64)
than patients with CHBV-ALF (median, 53; range, 33-
71; P < 0.001; Table 1). The AHBV-ALF group was
comprised mostly of Caucasians (31 of 60; 52%) and
African Americans (22 of 60; 37%), whereas Asians
accounted for only 2 of 60 (3%) of AHBV-ALFs. The
AHBV-ALF group included primarily genotypes A (24
of 47; 51%) and D (14 of 47; 30%), with only 4 and
2 patients, respectively, classiﬁed as genotype B or C.
By contrast, the CHBV-ALF group included a
much larger number of Asians (14 of 27; 52%) and,
as expected, mainly genotypes B (11 of 24; 46%) and
A (7 of 24; 29%). Mutations in the core promoter
region alone did not differ between the two groups,
AHBV-ALFs (15 of 48; 31%) versus CHBV-ALFs
(5 of 20; 25%) (P ¼ 0.606), whereas precore muta-
tions were signiﬁcantly more common in CHBV-ALFs
(10 of 20; 50%) versus AHBV-ALFs (10 of 47; 21%)
(P ¼ 0.019).
Admission Titers and Cut-off Value of IgM Anti-
HBc in AHBV-ALFs Versus CHBV-ALFs. Ninety-six
percent (44 of 46) of the AHBV-ALF patients had
positive IgM anti-HBc tests (index value, 1.0),
whereas 15 of 23 (65%) of those deemed to have
CHBV-ALF tested positive for IgM anti-HBc. Admis-
sion IgM anti-HBc index values in AHBV-ALFs (n ¼
46; median, 88.5; range, 0-1,120) were signiﬁcantly
higher than those of the CHBV-ALF group (n ¼ 23;
median, 1.3; range, 0-750) (P < 0.001) (Fig. 2).
Among patients with CHBV-ALF, 70% (16 of 23)
had index values <5. By contrast, 44 of 46 (96%) of
AHBV-ALFs demonstrated IgM anti-HBc index values
5. Based on these data, the proposed cut-off value of
IgM anti-HBc to best differentiate AHBV-ALF from
CHBV-ALF was 5.0. Using this cutoff, the percent
correct for the overall group was 87 with the AUROC
of 0.86 (P < 0.001) (curve not shown).
Admission and Serial HBV VLs in AHBV-ALF
Versus CHBV-ALF. Patients with AHBV-ALF dem-
onstrated lower admission log10 VLs (n ¼ 51;
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median, 3.9; range, 0-8.1 log10 IU/mL) than those
in the overall CHBV-ALF group (n ¼ 24; median,
5.2; range, 2.0-8.7 log10 IU/mL; Fig. 3); the dif-
ference in median levels between groups was
between 1 and 2 logs. Of note, there was consider-
able overlap of admission VLs between AHBV-ALFs
and CHBV-ALFs. There were 4 patients in the
AHBV-ALF category who had undetectable admis-
sion VLs by our assay (lower limit of detection
[LLD]: 25 IU/mL), compared to none with
CHBV-ALF. A difference was observed in the viral
loads for the two CHBV-ALF subgroups, in that
the nonimmunosuppressed group median VL was
similar to that of the acute group and less than
that of the immunosuppressed group, as might be
expected.
Overall, high IgM anti-HBc and low VLs character-
ized the AHBV-ALF group, whereas the opposite was
true of the CHBV-ALF subjects (Figs. 2 and 3).
Changes in VLs Over Time. Mean log10 VLs
declined signiﬁcantly for both groups at three time
points over 4 days (P < 0.001; Fig. 4). With relatively
low initial levels, the VLs in AHBV-ALFs continued
to decline and were consistently lower at all time
points than the mean CHBV-ALF log values (P <
0.001). The interaction between the two groups over
time was nonsigniﬁcant (P ¼ 0.360), and the only
covariate remaining in the ANCOVA model (P <
0.150) was admission IgM anti-HBc levels (P ¼
0.137).
Ratio of IgM Anti-HBc to HBV VL. The ratio of
IgM anti-HBc to HBV VL, calculated using admission
Table 1. Demographic and Baseline Characteristics of the Study Patients*
Characteristics
AHBV-ALF
(n ¼ 60)
CHBV-ALF
(n ¼ 27) P Value†
CHBV-ALF
Nonimmunosuppressed
(n ¼ 9) P Value‡
Age (years) 36 (17-64) 53 (33-71) <0.001 60 (46-69) <0.001
Race
African American 37 (22/60) 22 (6/27) <0.001 0 <0.001
Asian 3 (2/60) 52 (14/27) 67 (6/9)
Caucasian 52 (31/60) 22 (6/27) 22 (2/9)
Other 8 (5/60) 4 (1/27) 11 (1/9)
Female sex 47 (28/60) 37 (10/27) 0.402 22 (2/9) 0.281
ALT (IU/L) 1,954 (87-11,100) 1,008 (94-7,856) 0.018 826 (117-7,774) 0.069
AST (IU/L) 1,024 (66-9,901) 719 (78-8,615) 0.248 530 (98-7,420) 0.250
Bilirubin (mg/dL) 18.4 (3.6-62.4) 20.2 (5.7-36.0) 0.319 21.4 (7.5-30.4) 0.392
Albumin (g/dL) 2.8 (1.7-4.0) 2.5 (1.7-3.3) 0.006 2.4 (2.0-3.3) 0.056
INR 2.9 (1.2-20.1) 3.2 (0.9-10.3) 0.456 2.7 (0.9-9.4) 0.679
Hepatic coma grade
I and II 48 (29/60) 41 (11/27) 0.511 33 (3/9) 0.489
III and IV 52 (31/60) 59 (16/27) 67 (6/9)
Creatinine (mg/dL) 1.1 (0.4-8.6) 1.1 (0.6-10.5) 0.508 1.8 (0.6-6.6) 0.269
Days from jaundice to onset of hepatic coma 5 (0-46) 9.5 (0-28) 0.277 13 (1-28) 0.202
HBsAg negativity 20 (12/60) 0 (0/27) 0.015 0 (0/9) 0.342
HBeAg positivity 26 (15/57) 27 (7/26) 0.954 11 (1/9) 0.436
Anti-HBs positivity 28 (17/60) 15 (4/27) 0.173 11 (1/9) 0.428
HBV genotype
A 51 (24/47) 29 (7/24) 0.003 13 (1/8) <0.001
B 9 (4/47) 46 (11/24) 88 (7/8)
C 4 (2/47) 8 (2/24) 0
D 30 (14/47) 17 (4/24) 0
Other 6 (3/47) 0 0
HBV basal core promoter mutations (A1762T/G1764A) 31 (15/48) 25 (5/20) 0.606 29 (2/7) >0.999
HBV precore mutation (G1896A) 21 (10/47) 50 (10/20) 0.019 86 (6/7) 0.002
HBV precore 6 basal core promoter mutations 40 (19/47) 60 (12/20) 0.141 86 (6/7) 0.041
HBV VL, log10 (IU/mL) 3.9 (0.0-8.1) 5.2 (2.0-8.7) 0.025 3.8 (2.5-8.7) 0.982
IgM anti-HBc (index value) 88.5 (0-1,120) 1.3 (0-750) <0.001 1.9 (0-28.9) <0.001
N-acetylcysteine treatment 51 (30/59) 15 (4/27) 0.002 44 (4/9) >0.999
Acetaminophen use mentioned 80 (28/35) 60 (6/10) 0.228 67 (2/3) 0.519
Alcohol use 43 (25/58) 31 (8/26) 0.285 33 (3/9) 0.724
Nucleoside (tide) analogs use 53 (31/59) 78 (21/27) 0.026 89 (8/9) 0.068
Spontaneous survival 33 (20/60) 11 (3/27) 0.030 11 (1/9) 0.258
Overall 3-week survival 72 (43/60) 44 (12/27) 0.015 44 (4/9) 0.132
*Continuous data are shown as median (range) and categorical data are % (numerator/denominator).
†Comparison between AHBV-ALF versus overall CHBV-ALF.
‡Comparison between AHBV-ALF versus CHBV-ALF without immunosuppression (CHBV-ALF).
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values for each patient, was signiﬁcantly higher in
AHBV-ALF (median, 9.2  103; range, 0-1.1) than
in CHBV-ALF (median, 1.0  105; range, 0-2.0 
102; P < 0.001; AUROC, 0.86; P > 0.001). Logistic
regression analysis, considering VLs, IgM anti-HBc
titers, age, HBV genotypes (i.e., A, B, and D), and
HBsAg status upon admission, was employed to deter-
mine independent predictors of AHBV-ALF versus
CHBV-ALF. Admission log10 VLs (P ¼ 0.022; odds
ratio [OR], 0.569; 95% conﬁdence interval [CI]:
0.352-0.921), IgM anti-HBc (P ¼ 0.005; OR, 1.006;
95% CI: 1.002-1.010), and age (P < 0.001; OR,
0.855; 95% CI: 0.788-0.929) were independent deter-
minants that distinguished the groups (Hosmer-Leme-
show, P ¼ 0.812; AUROC ¼ 93%; P < 0.001).
There were 3 ‘‘outlier’’ patients in the CHBV-ALF
group who exhibited high IgM anti-HBc titers of 248,
337, or 750 index values with correspondingly high
HBV VLs on admission (1.21  103, 20.05  106,
and 9.70  106). However, the ratios of IgM anti-
HBc to HBV VLs were 2.04  102, 1.68  105,
and 7.73  105, respectively, suggesting that they
may, indeed, belong to the CHBV-ALF group. Two
were receiving an immunosuppressive agent and the
3rd had HIV coinfection.
HBsAg Status and Outcomes. All CHBV-ALF
patients were HBsAg positive, whereas 20% (12 of 60)
of AHBV-ALF had undetectable HBsAg on admission
(P ¼ 0.015). Median IgM anti-HBc index values and
log10 VL for the 12 HBsAg-negative patients were
125 (range, 17.2-840) and 3.55 (range, 0-8.09) log10
IU/mL, respectively. Spontaneous survival was signiﬁ-
cantly higher for AHBV-ALF patients (33%; 20 of 60)
than for those with CHBV-ALF (11%; 3 of 27) (P ¼
0.030). Overall survival was higher for AHBV-ALF
patients (72%; 43 of 60) than for those with CHBV-
ALF (44%; 12 of 27) (P ¼ 0.015). Admission HBeAg,
Fig. 2. IgM anti-HBc levels for the various groups. Admission IgM
anti-HBc levels were much higher in AHBV-ALFs than in the overall
CHBV-ALF group. Median IgM anti-HBc index value (S/N) on admis-
sion to hospital in the 46 AHBV-ALFs was 88.5 (range, 0-1,120), sig-
niﬁcantly higher than that of the 23 overall CHBV-ALFs (1.30 [0-750];
P < 0.001) or the 8 nonimmunosuppressed CHBV-ALFs [**] (1.9 [0-
28.9]; P < 0.001]. The median (range) value for the 15 immunosup-
pressed CHBV-ALFs [*] was 1.27 (0-750). There was no difference
observed between the two CHBV-ALF subgroups.
Fig. 3. HBV VLs for the various groups. Median admission VL in 51
patients with AHBV-ALF was 3.9 (0-8.1) log10 IU/mL, signiﬁcantly
lower than observed for the 24 patients in the overall CHBV-ALF group
(5.2 [2.0-8.7] log10 IU/mL; P ¼ 0.025), but not for the 8 nonimmu-
nosuppressed CHBV-ALF patients (3.8 [2.5-8.7] log10 IU/mL; P ¼
0.982). The median (range) for the 16 in the immunosuppressed sub-
group was 6.28 (1.97-8.28) log10 IU/mL. There were no signiﬁcant
differences in admission VLs between the two CHBV-ALF subgroups;
horizontal line in each bar graph represents median VL.
Fig. 4. ANCOVA for VLs measured over time for AHBV-ALF and the
overall CHBV-ALF groups, adjusting for baseline IgM anti-HBc levels.
The decrease in VLs was signiﬁcant for each of the two groups (P <
0.001). VLs in AHBV-ALFs were consistently lower than in CHBV-ALFs
at all time points (P < 0.001). Admission IgM anti-HBc level was the
only covariate that remained signiﬁcant in the ANCOVA model (P ¼
0.137). Error bars are 95% CIs.
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Anti-HBs positivity, and coma grade were comparable
between the two groups (Table 1). Follow-up (beyond
3 weeks) was available on 15 of 22 with AHBV-ALF
who had survived without grafting. This group would
be expected to clear HBsAg if they represented ‘‘true
acute’’ infections: 4 had died after 3 weeks, including
2 who had undergone liver grafting, and 4 had cleared
their infection, as indicated by negative HBsAg at 3
weeks to 18 months after infection (no earlier visits
for this patient). In 7, further follow-up failed to
include information on HBsAg clearance, and 7 others
were lost to follow-up.
Discussion
This study sought to describe, in more detail, the
clinical and immunological features of patients with
AHBV-ALF or CHBV-ALF in relation to their sero-
logical features and molecular biology, because distin-
guishing between the two forms might well have clini-
cal and pathogenetic signiﬁcance. There were at least
two distinct groups within the overall HBV-ALF
cohort, based on history obtained and certain key clin-
ical and histological features: One with newly acquired
acute HBV infection leading to ALF (illness <6
months, usually <2-4 weeks) and one in which ALF
had occurred in the setting of deﬁnite or presumed
chronic disease. The source of confusion has been that
the two forms resemble each other remarkably in clini-
cal and biochemical features, such as apparent rapid
onset of severe disease, advanced grades of encephalop-
athy, high aminotransferases, and prolonged INRs, and
thus cannot be distinguished readily without historical
information of chronicity or, by contrast, of recent
HBV exposure, both of which are often lacking.
Although we had made initial assessments on overall
gestalt, we revisited the data on each conditional ran-
dom ﬁeld using the algorithm described above, includ-
ing, as primary data, conﬁrming CHBV-ALF with ei-
ther previous knowledge of CHBV-ALF, whether the
patient was receiving chemotherapy, or had HIV coin-
fection. Next, we considered evidence of high-risk
behavior, age, and ethnicity to complete the picture.
This was not a 100% accurate proﬁling procedure,
because it was performed blindly with only clinical his-
torical data, with possible proof being that, by this
technique, 2 with negative IgM anti-HBc were classi-
ﬁed as being acute. However, at least 85% of our
assessments are likely to be accurate, based on these
criteria. Among those misclassiﬁed might be, for exam-
ple, a young patient with high-risk behavior who
might have CHBV-ALF. We were forced to exclude 15
patients from the original cohort because features
delineating acute from chronic could not be found. It
is well known, however, that ALF patient histories are
often limited by the presence of encephalopathy on ar-
rival at the referring hospital.
The acute form of HBV-ALF accounted for two
thirds of the overall group; CHBV-ALF comprised the
rest, 2 of 3 of whom were considered immunosup-
pressed. Other acute-on-chronic patients in the cohort
might have been excluded because they lacked
adequate history of chronicity. CHBV-ALF subjects
receiving immunosuppressive agents or coinfected with
HIV were considered together in this analysis. The
immunosuppressed group differed in only minor
respects from the remainder of the CHBV-ALF group.
However, one differentiating feature was VL, which
was lower in the nonimmunosuppressed group.
HBV VL, IgM anti-HBc titer, or the ratio of the
two (if both values are available) effectively distin-
guished the two forms of ALF resulting from HBV,
particularly the quantitation of IgM anti-HBc levels,
with an AUROC of 86%. In practice, the presence of
IgM anti-HBc positivity is associated with acute infec-
tion and is necessary, but not sufﬁcient, to diagnose
AHBV, because IgM anti-HBc is also observed, in
some patients, with exacerbation of chronic infec-
tion.10,14 Higher IgM anti-HBc titers have been sug-
gested to be associated with a highly active host
immune response. Quantitative IgM anti-HBc testing
more accurately distinguishes between acute and nona-
cute cases. Fink et al. showed that a strong immuno-
logic response promotes B-cell differentiation into
IgM-producing plasmablasts and high titers of IgM
antibody, whereas moderate or weak stimulation drives
differentiation into memory or plasma cells that
mostly produce the immunoglobin G isotype.15
Moreover, clinical studies have consistently suggested
that higher titers of IgM anti-HBc are observed in
new AHBV than in CHBV.16 The cut-off index value
for IgM anti-HBc of 5.0 in our study effectively differ-
entiated AHBV-ALF from CHBV-ALF with a positive
predictive value of 86% and a negative predictive value
of 89%. Though 35% of CHBV-ALF patients demon-
strated levels of IgM anti-HBc between 1.0 and 5.0
using the ADVIA assay (Siemens Diagnostics), 70%
were below the index value of 5.0. Given our current
knowledge, we suggest that determining the IgM anti-
HBc level with a quantitative assay or at least a higher
cut-off value than 1.0 is a readily available single test
with excellent predictive capacity.
Earlier studies describing rapid viral clearance with
undetectable HBsAg and VLs in HBV-related ALF
were based on insensitive tests, such as immunoelectro-
phoresis, radioimmunoassay, and, for VLs, dot blot
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hybridization, with an LLD of approximately 100,000
IU/mL.5,7 We could not ﬁnd recent studies that com-
pared VLs in either acute or fulminant hepatitis B
using current highly sensitive assays. Thus, we did not
have available known ranges for VL during AHBV or
CHBV leading to liver failure. Using an rt-PCR assay
with an LLD of 25 IU/mL, nearly all (92%; 47 of 51)
of our AHBV-ALF patients had a detectable HBV VL
on admission, although many had remarkably low val-
ues. AHBV-ALF subjects had signiﬁcantly lower VLs
than CHBV-ALF subjects, although there was some
overlap between groups. The reasons for this overlap
included possible inaccuracy of the initial clinical assess-
ment that categorized the patients and the overall heter-
ogeneity in timing of admission to study.
Lower VLs in AHBV-ALF, like higher IgM anti-
HBc levels, suggest a more robust immune response.
Though the CHBV-ALF group demonstrated higher
admission VLs (approximately 6 log10 IU/mL, com-
pared to 3-4 log10 IU/mL), nearly all values declined
during the study (Fig. 4). The ratio of IgM anti-HBc
to VL had a remarkably high AUROC of 0.86 (P <
0.001), but was no better than IgM anti-HBc alone
(AUROC ¼ 86%; P < 0.001).
Spontaneous survival differed between the two
groups: 11% in the CHBV-ALF group vs. 33% in the
AHBV-ALF patients, which might be the result of dif-
ferences in survival with older age. Overall survival was
similar between the two groups, largely because of the
increased numbers of CHBV-ALF patients receiving a
liver allograft.
A third feature of AHBV-ALF is early HBsAg clear-
ance, observed in 20% (12 of 60) of patients with
AHBV-ALF and in none with CHBV-ALF.7 Those
who cleared HBsAg demonstrated higher median IgM
anti-HBc titers and lower HBV VLs than their peers.
The combination of lower VL, high IgM anti-HBc
titers, and low or undetectable HBsAg on admission in
AHBV-ALF suggests that a more robust host immune
response occurs in true acute patients than is observed
in CHBV presenting as ALF. Based on these data, it
may be useful for clinicians to differentiate AHBV-
ALF and CHBV-ALF on clinical and serological
grounds, either by use of the IgM anti-HBc titers, VLs
or, if available, the ratio of the two. As a single value,
IgM anti-HBc appears to be robust using the 5.0 cut-
off value. Of interest, the immunosuppressed chronic
group were mixed in ethnicity, whereas virtually all
remaining acute-on-chronic nonimmunosuppressed
patients were of Asian heritage, B genotype (7 of 8),
and demonstrated precore (6 of 7) and/or basal core
promoter mutations.
As expected, the algorithm we used resulted in an
increased number of Asian patients in the CHBV-ALF
group, and nearly 50% of CHBV-ALF patients had
genotype B. Studies from Asia suggest that genotype B
is associated with more frequent acute exacerbations
and a higher risk of hepatic decompensation and mor-
tality, compared to genotype C, whereas genotype C is
associated with more liver cirrhosis and HCC.17,18
Among Asian patients with presumed AHBV, more ge-
notype B patients developed a fulminant course; this
was conﬁrmed in our non-immunosuppresed CHB-
ALF patients, with 7 of 8 being genotype B.19
Precore (G1896A) and core promoter (A1762T/
G1764A) mutations have been considered drivers of
severe disease, although these mutations are also found
in chronic or asymptomatic HBV infection.20 A low
prevalence of these mutations was detected in two pre-
vious series of HBV-related ALF.21 However, once the
groups were separated in our study, it appeared that
60% of CHBV-ALFs (and all but 1 of the nonimmu-
nosuppressed CHBV-ALFs) presented with either pre-
core, core promoter mutations, or both, as compared
to 40% of AHBV-ALFs—this was not statistically sig-
niﬁcant. These ﬁndings may point to the different
immunopathogenesis in CHBV-ALF, compared to the
truly acute cases. Though these data were obtained on
consecutive U.S. patients, the patient characteristics
observed here are likely unique to the United States
and not readily extrapolated to other populations.
Our study had several limitations. Histories are of-
ten limited in rapidly evolving severe illnesses, such as
ALF, where altered mentation is a criterion for study
entry. The case-selection process likely had inaccuracies
as noted, because the distinction between AHBV-ALF
and CHBV-ALF was based solely on patient history
and demographics. Finally, the ADVIA Centaur IgM
Anti-HBc assay used is considered to be semiquantita-
tive and was adapted for the quantitation performed
here. Nevertheless, the wide differences observed in
IgM anti-HBc between the two groups are clear,
because the majority of CHBV-ALF patients demon-
strated low IgM anti-HBc titers that were within the
ﬁrst dynamic range (no dilution needed).
In conclusion, AHBV-ALF can be separated from
CHBV-ALF on clinical grounds when valid historical
data are available, but the two may be more readily
distinguished by quantitative IgM anti-HBc, VLs, and/
or IgM anti-HBc/VL ratios. Additional indicators,
such as HBsAg negativity, younger age, non-Asian,
and genotype non-B, provide indirect evidence of
AHBV-ALF. By contrast, a low or undetectable IgM
anti-HBc level, with elevated HBV DNA VL to >5
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log10 IU/mL, in a patient with what appeared to be
an acute illness, suggest that this patient probably
actually suffered from CHBV-ALF. Overall, HBV-
related ALF patients carry a poor prognosis, although
those with new acute infection appear to fare some-
what better than those with chronic disease. Differen-
tiation between the two subtypes within HBV-ALF
may be helpful in determining more appropriate thera-
peutic strategies.
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